strive pharmacy tirzepatide says it will not resume compounded oral semaglutide sales COMPOUND TIRZEPATIDE BREAKING NEWS! -

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition

Patients should be counseled to contact their healthcare provider if they experience any of the following: Severe or persistent gastrointestinal symptoms including intractable nausea or vomiting lasting more than 24-48 hours, inability to maintain adequate oral hydration, severe abdominal pain (particularly if localized to the upper abdomen or radiating to the back), or signs of gastrointestinal bleeding such as bloody or black stools

Anyone considering these peptides should exercise caution, consult qualified healthcare professionals, and prioritize high quality sources

WHO IS A CANDIDATE

Your healthcare provider can help you find ways to minimize discomfort while your body adjusts to the medication